Where does Gabriel Ocana Santero work?

Gabriel Ocana Santero is Founder of Exin Therapeutics.

What companies did Gabriel Ocana Santero found?

Gabriel Ocana Santero founded Exin Therapeutics.

Where did Gabriel Ocana Santero go to school?

Gabriel Ocana Santero studied at University of Oxford (Doctor of Philosophy - PhD, Pharmacology); Y Combinator (W25, Biotechnology); University of Oxford (Master of Science - MS, Neuroscience).

Gabriel Ocana Santero

Founder

Founder at Exin Therapeutics

South San Francisco, California, United States

FoundedExin Therapeutics · YC

Find your path to Gabriel

1,226 people in our graph share verified history with Gabriel — schools, employers, funds. One of them is your warm intro.

Garry TanunlockedGabriel: together at Y Combinator (2025)

×9Gabriel: together at Y Combinator

×2Gabriel: together at Universidad Autónoma de Madrid

About

Gabriel Ocana Santero holds an MSc in Neuroscience and PhD in Pharmacology from Oxford University, with research experience spanning gene therapy, pancreatic cancer, and muscle physiology at institutions in Boston, Vienna, and Stockholm. He has conducted work on neurodevelopment and serotonin signaling at the Gatsby Unit at UCL, and now develops gene therapies for neurological conditions at Exin Therapeutics.

Founder at Exin Therapeutics YC W25

Intro paths

Gabriel went through Y Combinator (Winter 2025) — any YC alum in your network can reach them through the YC community.

Their group partner at YC was Jared Friedman, YC Group Partner — the partner who ran Exin Therapeutics's batch and knows the company first-hand. YC profile ↗

→

In turn, Gabriel can intro founders to Exin Therapeutics's investors below.

Exin Therapeutics's investors · 2

468 CapitalBerlin · since 2024 Y CombinatorSan Francisco · $500K checks · since 2025

Co-founders at Exin Therapeutics

Marko TvrdicFounder

Ivan Alex Priela LazarteExecutive Officer, Director

Experience

Exin TherapeuticsCEO and Co-foundercurrent2025 — presentSan Francisco Bay Area
Serotonin and BEYONDSerotonin and Beyond Early Stage Researcher2021 — 2024Oxford, England, United Kingdom
Gatsby Computational Neuroscience UnitNeuroAI Research Internship2023Greater London, England, United Kingdom
Fundación "la Caixa"Postgraduate Studies' Fellowship Holder2020 — 2021Oxford, England, United Kingdom
Centro de Biología Molecular Severo Ochoa, CBMSOResearch Intern2020Greater Madrid Metropolitan Area
Karolinska InstitutetResearch Intern2019Greater Stockholm Metropolitan Area
Medical University of ViennaResearch Intern2018Austria

Skills & more

Python (Programming Language)Machine LearningArtificial Neural NetworksInvestigaciónDocenciaAptitudes de laboratorioCancer ResearchLeadership

Languages English · French · Spanish

The Science and Business of Biotechnology — MITx Courses
TOEFL-ibt (113/120) — TOEFL

From Gabriel's professional profile.

Frequently asked questions

Who is Gabriel Ocana Santero?: Gabriel Ocana Santero holds an MSc in Neuroscience and PhD in Pharmacology from Oxford University, with research experience spanning gene therapy, pancreatic cancer, and muscle physiology at institutions in Boston, Vienna, and Stockholm. He has conducted work on neurodevelopment and serotonin signaling at the Gatsby Unit at UCL, and now develops gene therapies for neurological conditions at Exin Therapeutics.
Where does Gabriel Ocana Santero work?: Gabriel Ocana Santero is Founder of Exin Therapeutics.
What companies did Gabriel Ocana Santero found?: Gabriel Ocana Santero founded Exin Therapeutics.
Where did Gabriel Ocana Santero go to school?: Gabriel Ocana Santero studied at University of Oxford (Doctor of Philosophy - PhD, Pharmacology); Y Combinator (W25, Biotechnology); University of Oxford (Master of Science - MS, Neuroscience).